Stock PHAT PHATHOM PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Phathom Pharmaceuticals, Inc.

Equities

PHAT

US71722W1071

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
9.18 USD +0.88% Intraday chart for Phathom Pharmaceuticals, Inc. +2.34% +0.55%
Mar. 07 Transcript : Phathom Pharmaceuticals, Inc., Q4 2023 Earnings Call, Mar 07, 2024
Mar. 07 Phathom Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI

Business Summary

Phathom Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases. The Company’s pipeline product candidate, VOQUEZNA, VOQUEZNA TRIPLE PAK, and VOQUEZNA DUAL PAK. Its product candidate, VOQUEZNA, contains vonoprazan, an oral small molecule potassium-competitive acid blocker (PCAB). PCABs are a novel class of medicines that block acid secretion in the stomach. Vonoprazan has also demonstrated clinical benefits in the treatment of erosive gastroesophageal reflux disease (erosive GERD), and in combination with antibiotics for the treatment of Helicobacter pylori (H. pylori) infection. GERD and H. pylori infection are two of the most common acid-related GI diseases. GERD is a disease that develops when the reflux of acidic stomach contents causes troublesome symptoms and/or complications. H. pylori is a bacterial pathogen.

Number of employees: 452

Sales per Business

USD in Million2022Weight2023Weight Delta
Vonoprazan
100.0 %
0 nan % 1 100.0 % -

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
0 nan % 1 100.0 % -

Managers

Managers TitleAgeSince
Azmi Nabulsi FOU
 Founder 64 18-01-08
Terrie Curran CEO
 Chief Executive Officer 55 19-07-31
David Socks FOU
 Founder 49 18-01-08
Molly Henderson DFI
 Director of Finance/CFO 54 22-04-04
Eckhard S. D. Leifke CTO
 Chief Tech/Sci/R&D Officer 60 19-12-01
Eric Sciorilli IRC
 Investor Relations Contact - -
Martin J. Gilligan PRN
 Corporate Officer/Principal - 20-01-05
Tom Harris PRN
 Corporate Officer/Principal - -

Members of the board

Members of the board TitleAgeSince
Heidi Fields BRD
 Director/Board Member 69 19-09-26
Frank Karbe BRD
 Director/Board Member 56 22-04-24
Michael Cola CHM
 Chairman 64 19-09-26
James Topper BRD
 Director/Board Member 62 17-12-31
David Socks FOU
 Founder 49 18-01-08
Terrie Curran CEO
 Chief Executive Officer 55 19-07-31
Asit Parikh BRD
 Director/Board Member 52 19-11-30
Mark Stenhouse BRD
 Director/Board Member 57 20-03-16

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 58,543,101 52,883,556 ( 90.33 %) 19,000 ( 0.0325 %) 90.33 %

Shareholders

NameEquities%Valuation
Frazier Life Sciences Management LP
17.29 %
10,109,279 17.29 % 107 M $
Medicxi Ventures (Jersey) Ltd.
12.76 %
7,464,572 12.76 % 79 M $
Abingworth LLP
5.980 %
3,496,808 5.980 % 37 M $
Invesco Advisers, Inc.
5.417 %
3,167,653 5.417 % 34 M $
TAKEDA PHARMACEUTICAL COMPANY LIMITED
4.772 %
2,790,480 4.772 % 30 M $
BlackRock Advisors LLC
4.260 %
2,491,133 4.260 % 26 M $
Ensign Peak Advisors, Inc.
3.899 %
2,280,000 3.899 % 24 M $
NEA Management Co. LLC
3.352 %
1,960,169 3.352 % 21 M $
Vanguard Fiduciary Trust Co.
3.346 %
1,956,429 3.346 % 21 M $
Avidity Partners Management LP
2.944 %
1,721,580 2.944 % 18 M $

Company contact information

Phathom Pharmaceuticals, Inc.

100 Campus Drive Suite 102

07932, Florham Park

+

http://www.phathompharma.com
address Phathom Pharmaceuticals, Inc.(PHAT)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Ratings for Phathom Pharmaceuticals, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
9.18 USD
Average target price
22 USD
Spread / Average Target
+139.65%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
PHATHOM PHARMACEUTICALS, INC. Stock Phathom Pharmaceuticals, Inc.
+0.55% 537M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. PHAT Stock
  4. Company Phathom Pharmaceuticals, Inc.